Health Canada authorizes LAZCLUZE plus RYBREVANT for chemo free lung cancer treatment

Posted on by wpadmin
New Cancer Treatment

wildpixel

  • Johnson & Johnson (JNJ) said on Monday that Health Canada has authorized LAZCLUZE in combination with RYBREVANT for chemotherapy-free treatment of non-small cell lung cancer with genetic mutations.
  • Janssen, a Johnson & Johnson company, is the market authorization holder for LAZCLUZE and RYBREVANT in

Leave a Reply

Your email address will not be published. Required fields are marked *